Literature DB >> 10212894

In vitro neurotoxicity of artemisinin derivatives.

W G McLean1, S A Ward.   

Abstract

The known neurotoxicity of high doses of arteether and dihydroartemisinin in experimental animals has led to the need for a rapid screening method to predict the potential neurotoxicity of newly developed artemisinin-related antimalarial drugs. We have studied the effects of a range of these compounds on the neurite outgrowth of differentiating NB2a neuroblastoma cells in vitro, an assay that shows a correlation with neurotoxicity in vivo for a range of neurotoxic agents. In this assay, dihydroartemisinin is significantly more toxic than artemether or arteether. In the presence of liver metabolising enzymes, in vitro neurotoxicity of artemether and arteether is markedly increased. Differentiated neuronal cells are more sensitive than differentiated glial cells. Electron microscopy confirms that the targets in the neuronal cell for dihydroartemisinin are mitochondrial membranes and endoplasmic reticulum. The technique forms a valuable component of a range of appropriate neurotoxicity screening tests that should continue to be applied to newly developed antimalarials of this type.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10212894

Source DB:  PubMed          Journal:  Med Trop (Mars)        ISSN: 0025-682X


  6 in total

1.  Neurotoxic mode of action of artemisinin.

Authors:  Gabriele Schmuck; Elke Roehrdanz; Richard K Haynes; Regine Kahl
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

2.  First assessment in humans of the safety, tolerability, pharmacokinetics, and ex vivo pharmacodynamic antimalarial activity of the new artemisinin derivative artemisone.

Authors:  Johannes Nagelschmitz; Barbara Voith; Georg Wensing; Axel Roemer; Burkhard Fugmann; Richard K Haynes; Barbara M Kotecka; Karl H Rieckmann; Michael D Edstein
Journal:  Antimicrob Agents Chemother       Date:  2008-06-16       Impact factor: 5.191

Review 3.  Antitumor activity of artemisinin and its derivatives: from a well-known antimalarial agent to a potential anticancer drug.

Authors:  Maria P Crespo-Ortiz; Ming Q Wei
Journal:  J Biomed Biotechnol       Date:  2011-11-22

4.  Pharmacokinetic evaluation of intravenous artesunate in adults with uncomplicated falciparum malaria in Kenya: a phase II study.

Authors:  Qigui Li; Shon Remich; Scott R Miller; Bernhards Ogutu; Walter Otieno; Victor Melendez; Paktiya Teja-Isavadharm; Peter J Weina; Mark R Hickman; Bryan Smith; Mark Polhemus
Journal:  Malar J       Date:  2014-07-22       Impact factor: 2.979

5.  Pharmacokinetics, tissue distribution and mass balance of radiolabeled dihydroartemisinin in male rats.

Authors:  Lisa H Xie; Qigui Li; Jing Zhang; Peter J Weina
Journal:  Malar J       Date:  2009-05-26       Impact factor: 2.979

6.  Pharmacokinetic profiles of artesunate following multiple intravenous doses of 2, 4, and 8 mg/kg in healthy volunteers: phase 1b study.

Authors:  Robert Scott Miller; Qigui Li; Louis R Cantilena; Kevin J Leary; George A Saviolakis; Victor Melendez; Bryan Smith; Peter J Weina
Journal:  Malar J       Date:  2012-08-01       Impact factor: 2.979

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.